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Abstract: Peripheral artery disease (PAD) is due to the blockage of the arteries supplying 
blood to the lower limbs usually secondary to atherosclerosis. The most severe clinical 
manifestation of PAD is critical limb ischemia (CLI), which is associated with a risk of 
limb loss and mortality due to cardiovascular events. Currently CLI is mainly treated by 
surgical or endovascular revascularization, with few other treatments in routine clinical 
practice. There are a number of problems with current PAD management strategies, such 
as the difficulty in selecting the appropriate treatments for individual patients. Many 
patients undergo repeated attempts at revascularization surgery, but ultimately require  
an amputation. There is great interest in developing new methods to identify patients who 
are unlikely to benefit from revascularization and to improve management of patients 
unsuitable for surgery. Circulating biomarkers that predict the progression of PAD and the 
response to therapies could assist in the management of patients. This review provides an 
overview of the pathophysiology of PAD and examines the association between circulating 
biomarkers and PAD presence, severity and prognosis. While some currently identified 
circulating markers show promise, further larger studies focused on the clinical value of 
the biomarkers over existing risk predictors are needed. 
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1. Introduction 
Narrowing or blockage of the arteries supplying blood to the lower limbs, usually termed peripheral 
artery disease (PAD), is principally caused by athero-thrombosis. PAD is a leading cause of morbidity 
due to the associated functional decline and limb loss. Both asymptomatic and symptomatic PAD  
are significant predictors of cardiovascular disease (CVD) events and mortality [1]. Current evidence 
suggests that PAD represents a CVD risk equivalent to or worse than coronary artery disease requiring 
aggressive medical management [2]. 
The main recognized clinical presentations of PAD are intermittent claudication (IC) and critical 
limb ischemia (CLI). IC describes the symptoms of pain in the muscles of the lower limb brought on 
by physical activity which is rapidly relieved by rest. CLI is a more severe manifestation of PAD, 
which presents as rest pain, ischemic ulceration or gangrene of the foot. Patients with CLI have a high 
risk of limb loss and fatal or non-fatal vascular events, such as myocardial infarction (MI) and stroke [2]. 
Acute limb ischemia (ALI) occurs when there is a sudden interruption of blood flow to a limb typically 
due to an embolism or thrombosis [3]. In contrast to CLI, which typically develops over a prolonged 
period often preceded by IC, patients with ALI may not have preceding symptoms. ALI usually 
threatens limb viability more urgently than CLI possibly due to the absence of an established collateral 
blood supply to the limb. 
2. Epidemiology of PAD 
The prevalence of PAD is estimated to be 10%–25% in people aged ≥55 years and increases to 
approximately 40% in community populations aged >80 years [4,5]. Approximately 4–8 million 
people are affected by PAD in the United States of America [6–8]. In Germany around 1.8 million 
people have symptomatic PAD and each year between 50,000 to 80,000 patients develop CLI [9,10]. 
In a population-based study in Western Australia, the prevalence of PAD was reported to be 
approximately 23% in men aged 75–79 years [4]. Recent reports suggest that the burden of PAD has 
increased globally over the last decade [11–13]. Atherosclerosis induced CLI has been associated  
with a mortality rate of 20%–25% in the first year after presentation and a survival rate of less than 
30% at five years [14–19]. Previous reports suggest that CLI patients have a three-year limb loss rate 
of about 40% [20–23]. 
Recurrent CLI due to the failure of lower extremity revascularization is associated with a poor 
outcome [24,25]. In the Bypass versus Angioplasty in Severe Ischemia of the Leg (BASIL, n = 216) 
trial, the re-intervention rate in 216 patients with CLI treated by percutaneous transluminal angioplasty 
was 26% at 12 months [14]. Reasons for revascularization failure include restenosis, and residual and 
progressive atherosclerosis. Approximately 20%–30% of CLI patients are not ideal candidates for 
interventional procedures for a number of reasons such as the distribution of the occlusive disease and 
the patient’s co-morbidities [26]. Patients with CLI represent a small subset of the total PAD population 
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however the high incidence of CVD events, repeated requirement for medical attention and high 
amputation rates lead to significant health service costs associated with these individuals [27,28]. 
Improvements in the current management of PAD are needed on many levels including earlier diagnosis, 
development of novel effective therapies and better application of currently available treatments. 
3. Risk Factors for PAD 
Approximately 70% of PAD cases can be explained by established risk factors such as older age, 
hypertension, dyslipidemia, cigarette smoking and diabetes [29]. It has been reported that for every 1% 
increase in hemoglobin A1c there is a corresponding 26% increase in PAD risk [30]. Insulin resistance 
has been identified as a risk factor for PAD even in subjects without diabetes [31]. The association 
between sex and PAD is less clear. The prevalence of asymptomatic or symptomatic PAD is slightly 
greater in men than in women and the incidence increases with increasing age [17]. Women have been 
reported to have a more advanced CLI stage at presentation (odds ratio (OR), 1.21; 95% confidence 
interval (CI): 1.21–1.23) [32]. Black ethnicity has been reported to increase the risk of PAD by over 
two fold [17]. There is also reported to be an association between underserved communities and major 
amputations due to PAD (adjusted OR, 1.29, 95% CI: 1.16–1.44) [33]. Cigarette smoking has been 
strongly associated with PAD incidence and heavy smokers have a four-fold higher risk of developing 
IC compared to non-smokers [17]. PAD thus shares risk factors with other CVDs, such as coronary 
artery disease, however some risk factors, such as smoking, are more powerfully associated with PAD 
than other CVDs. 
4. Current PAD Management Strategies 
PAD management focuses in part on the reduction of CVD risk factors [34,35]. A number of lower 
extremity performance measures have been suggested as prognostic markers in PAD and may be 
useful to identify patients at increased mortality risk [36]. Supervised exercise programs have been 
established as effective ways to increase pain free walking distance among patients with IC although 
they are not widely implemented [36]. Other medical therapies are applied to control pain, treat 
infection and promote ulcer healing. Revascularization, via endovascular means (e.g., percutaneous 
transluminal angioplasty or stenting) or open surgery (e.g., bypass), is the main treatment option for 
patients with CLI. Up to 30% of patients are not considered ideal for such interventions [26], the main 
reasons being unfavorable vascular involvement and peri-operative risk [37]. Previous studies suggest 
that endovascular and open surgical therapies provide similar outcomes for CLI. A recent meta-analysis 
of 23 studies reported no difference in amputation-free survival at three years (OR, 1.22, 95% CI: 
0.84–1.77) and all-cause mortality (OR, 1.07, 95% CI: 0.73–1.56) in patients with CLI treated by 
endovascular or surgical revascularization [38]. 
There is current interest in the development of novel therapies to improve arteriogenesis (collateral 
formation) and/or angiogenesis (capillary formation) in patients with PAD [19]. A number of approaches 
are currently being investigated including gene therapies and cell-based therapies [26,39,40]. It was 
reported for example that intramuscular injection of autologous bone marrow mononuclear cells 
resulted in a three-year amputation free rate of 60% with significant improvement in ischemic leg  
pain and walking distance in the therapeutic angiogenesis by cell transplantation (TACT) trial [41].  
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In another recent trial, the use of tissue repair cells in patients with PAD (RESTORE-CLI), it was 
reported that administration of patient-derived bone marrow mononuclear cells led to an amputation 
free survival improvement of 32% [42]. These novel therapeutic approaches are promising strategies 
for CLI patients who are not ideal candidates for traditional revascularization procedures. 
5. The Pathophysiological Response to Athero-Thombosis-Induced PAD 
PAD is mainly caused by atherosclerosis and associated thrombosis within the lower limb arteries 
leading to end organ ischemia. Other causes include vasculitis and in situ thrombosis related to 
hypercoagulable states. The pathophysiology of athero-thrombosis induced PAD is complex, and 
involves a large number of cells, proteins and pathways. Important cells contributing to or controlling 
the development of athero-thrombosis include vascular endothelial cells (ECs), vascular smooth muscle 
cells (SMCs), fibroblasts, platelets, resident stem cells, pericytes and inflammatory cells [43–45]. The 
pathophysiology of atherosclerosis has been described in detail in previous reviews [46–48]. 
Under healthy conditions the response to gradually progressive limb ischemia involves the promotion 
of angiogenesis and arteriogenesis in an attempt to increase the blood supply to the affected limb. 
Vascular remodeling, inflammation and apoptotic pathways are also implicated in the ischemic 
response and these may in part contribute to the resolution of tissue damage. In patients with CLI these 
compensatory responses to ischemia are ineffective. As a result, there is on-going inadequate perfusion 
of tissue, endothelial dysfunction, chronic inflammation and high levels of oxidative stress. All these 
changes lead to mitochondrial injury, free radical generation, muscle fibre damage, myofibre degeneration 
and fibrosis, and tissue damage, which may present as gangrene [49–53] (Figure 1). 
Arteriogenesis is the process of enlargement of pre-existing collateral arteries to contribute to tissue 
perfusion [54]. The primary driving force is the increased laminar blood flow or shear stress associated 
with redistribution of flow as a result of the reduction in downstream luminal pressure. The increase in 
shear stress promotes vessel enlargement [55], which is stimulated by activation of nitric oxide (NO) 
signaling and likely other signaling responses to flow [56,57]. Angiogenesis describes the development 
of new capillary networks. An important driving force for angiogenesis is tissue ischemia. In response 
to local hypoxia in the ischemic limb, sprouting of small endothelial tubes occurs from pre-existing 
capillary beds. A number of hypoxia-inducible growth factors play a role in this process, such as 
vascular endothelial growth factor (VEGF) and hypoxia inducible factor (HIF)-1α [58] (Figure 1). 
Potential therapies designed to accelerate arteriogenesis and angiogenesis during ischemia are under 
intense investigation although most of these interventions have not developed to a stage that they are 
ready for widespread clinical use [59–62]. 
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Figure 1. Schematic representation of the response to ischemia in peripheral artery disease. 
Initially the ischemic limb tries to compensate and resolve the hypoxia by changing the 
hemodynamics and promoting microvascular adaptations by promoting angiogenesis and/or 
arteriogenesis. As the severity of the hypoxia increases, the microvascular adaptations are not 
able to compensate. All these changes lead to mitochondrial injury and free radical generation 
and subsequent muscle fibre damage, myofibre degeneration and fibrosis. These changes 
eventually result in decreased oxygen supply and increased metabolic demands leading to 
conditions such as rest pain, chronic non-healing wounds and gangrene, subsequently 
threatening the limb function and viability. Blue arrows show the direction of blood flow in 
the artery and white arrows shows the increase in severity of disease. Abbreviations: ECs, 
endothelial cells; HIF-1α, Hypoxia inducible factor-1α; NO, Nitric oxide; PAD, Peripheral 
artery disease; VEGF, Vascular endothelial growth factor WBCs, white blood cells. 
6. Potential Biomarkers for PAD 
PAD is usually diagnosed using clinical assessment, ankle brachial pressure index (ABI) measurement 
or radiological imaging, or both, depending on the setting of the patient. Each of these approaches has 
advantages and disadvantages. ABI for example is a simple and cheap investigation to diagnose PAD 
but not applied frequently in routine practice [63,64]. Patients with IC alone typically have an ABI of 
0.5–0.9, while CLI patients usually have an ABI of <0.4 [23]. Angiography provides detailed imaging 
of the lower limb arteries but it is more expensive and involves exposure to radiation. The introduction 
of circulating markers which can diagnose PAD or predict patient outcomes has been suggested as  
a means to overcome some of the limitations of current approaches. 
A range of circulating markers of atherosclerosis, arterial stiffness, inflammation, angiogenesis, 
vascular extra cellular matrix (ECM) remodeling, endothelial dysfunction and oxidative stress have 
been reported to be associated with PAD. Some of these biomarkers have also been suggested to be 
useful in predicting disease severity and prognosis. 
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6.1. Circulating Markers Associated with the Presence of PAD 
Case-control studies have reported the association of a number of circulating markers with PAD 
presence (Table 1). 
Table 1. Examples of circulating biomarkers reported to be associated with peripheral artery disease. 
Circulating 
Biomarkers Assessed 
Sample Size (N) 
Sample 
Studied 
Association with PAD Presence Refs. 
B2M & cystatin C  
CAD & PAD (197); CAD (81)  
& healthy controls (262) 
Plasma 
A biomarker panel comprising B2M, 
cystatin C, hsCRP and glucose were 
associated with PAD. 
[65] 
B2M, cystatin C, 
hsCRP & glucose 
PAD (83) & controls (896) Plasma 
Levels of cystatin C and B2M but not 
hsCRP and glucose were significantly 
elevated in PAD patients. 
[66] 
aPWV, AIx & B2M PAD (66) & healthy controls (66) Plasma 
B2M, aPWV and AIx were 
significantly increased in patients with 
PAD; among patients with PAD 
elevated B2M levels were 
independently associated with higher 
aortic stiffness. 
[67] 
hsCRP, fibrinogen & 
leukocyte count 
The National Health and Nutrition 
Examination Survey 1999–2002  
(4787 participants aged ≥ 40 years) 
Blood 
All 3 markers were independently 
associated with PAD. 
[68] 
hsCRP PAD (82) & healthy controls (41) Plasma Increased hsCRP levels in PAD patients. [69] 
CD40 ligand, 
fibrinogen, Lp-PLA2 , 
osteoprotegerin,  
P-selectin, and TNF-R2, 
hsCRP, ICAM-1, IL-6, 
MCP-1 & MPO 
Framingham Offspring  
Study participants (2800) 
Plasma 
IL-6 &TNF-R2 were associated  
with PAD independent of established 
risk factors. 
[70] 
VEGF-A,  
TNF-α & IL-8 PAD (130) & controls (36) Serum 
Lower VEGF-A and higher TNF-α & 
IL-8 in PAD patients. 
[71] 
High molecular 
weight & total 
adiponectin  
PAD (110) & healthy controls (230) Plasma Lower adiponectin in women with PAD. [72] 
OxPL/ApoB & Lp-a 
Men with PAD (143), women with  
PAD (144) & controls (432) 
Plasma 
Increased levels of OxPL/ApoB and 
Lp-a were associated with PAD. 
[73] 
Lp-PLA2 activity PAD (172) & healthy controls (787) Plasma 
Increased Lp-PLA2 activity in  
PAD patients. 
[74] 
Lp-PLA2 level PAD (145) & healthy controls (837) Plasma 
Lp-PLA2 levels were significantly 
associated with PAD. 
[75] 
NOx &, sNOX2-dp PAD (50) & healthy controls (50) Serum 
NOX2 up-regulation is associated with 
artery dysfunction in PAD. 
[76] 
NO PAD (82) & healthy controls (41) Plasma 
Increased NO levels & hsCRP levels 
in PAD patients. 
[69] 
TBARS & ICAM-1 PAD (31) & healthy controls (10) Plasma Increased in PAD. [77] 
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Table 1. Cont. 
Circulating 
Biomarkers Assessed 
Sample Size (N) 
Sample 
Studied 
Association with PAD Presence Refs. 
Rho-kinase activity  
PAD (40), combined CAD/PAD (40) & 
healthy controls (40) 
Circulating 
leukocytes 
Increased in PAD.  [78] 
HCgp-39 PAD (316) & healthy controls (39)  Plasma 
Median levels of HCgp-39 were 
significantly higher in PAD patients.  
[79] 
CD163 & TWEAK PAD (155) & healthy controls (251) Plasma  
Decreased TWEAK level and higher 
sCD163 levels in PAD patients.  
[80] 
PON-3 PAD (118), CAD (72) & healthy controls (175) Serum Increased in PAD. [81] 
IL-6, E-selectin, 
MMP-2, MMP-9 & 
TGF-β1 
PAD (80) & healthy controls (3076) Plasma 
Increased levels of IL-6, E-selectin, 
MMP-2 & MMP-9 and reduced levels 
of TGF-β1 in PAD patients. 
[82] 
sRAGE  PAD (201) & healthy controls (201) Plasma 
Decreased levels of sRAGE in  
PAD patients. 
[83] 
VEGF PAD (293) & healthy controls (26) Serum 
Higher levels of VEGF in  
PAD patients. 
[84] 
Ang2, sTie2, VEGF, 
sVEGFR-1 & PlGF  
PAD (46) & healthy controls (23) Plasma 
Levels of VEGF and sTie2 were 
significantly increased in PAD patients. 
[85] 
VEGF, PlGF & TSP-1  PAD (184) & healthy controls (330) Plasma 
Elevated TSP-1 levels associated  
with PAD.  
[86] 
VEGF-A,  
TNF-α & IL-8 PAD (130) & controls (36) Serum 
PAD patients have lower circulating 
VEGF-A and higher levels of TNF-α 
and IL-8. 
[71] 
EPCs, CD133, 
VEGFR-2,  
MDA-LDL & 
pentraxin-3  
PAD (48) & healthy controls (22) 
Serum & 
Plasma 
EPCs and pentraxin-3 were increased 
in PAD patients; Cardiovascular 
events in PAD patients were 
associated with reduced EPC and 
increased MDA-LDL. 
[87] 
EPCs PAD (45) & healthy controls (24) Blood 
The number and proliferative activity 
of circulating EPCs was significantly 
increased in PAD patients. 
[88] 
Abbreviations: AIx, Augmentation index; Ang2, Angiopoietin-2; Apwv, Aortic pulse wave velocity; B2M,  
β-2-microglobulin; CAD, Coronary artery disease; EPC, Endothelial progenitor cell; HCgp, Human cartilage 
glycoprotein; hsCRP, high-sensitivity C-reactive protein; ICAM, Intercellular adhesion molecule; IL, 
Interleukin; Lp-a, Lipoprotein-a; Lp-PLA2, Lipoprotein-associated phospholipase A2; MCP-1, Monocyte 
chemotactic protein 1; MDA-LDL, Malondialdehyde-modified low-density lipoprotein; MMP, Matrix 
metalloproteinase; MPO, Myeloperoxidase; NOx, Nitrite/nitrate; NO, Nitric oxide; OxPL/ApoB, Oxidized 
phospholipids on Apo-B100-containing lipoproteins; PAD, Peripheral artery disease; PlGF, Placenta growth 
factor; PON-3, Paraoxonase-3; sNOX2-dp, soluble nicotinamide adenine dinucleotide phosphate oxidase  
2-derived peptide; sRAGE, Receptor for advanced glycation end products; sTie2, soluble Tyrosine kinase 
with immunoglobulin-like and EGF-like domains 2; sVEGFR, soluble VEGF receptor; TGF-β, Transforming 
growth factor-β; TNF, Tumour necrosis factor; TNFR2, Tumour necrosis factor receptor 2; TBARS, 
Thiobarbituric acid-reactive substances; TSP, Thrombospondin; TWEAK, Tumour necrosis factor-like weak 
inducer of apoptosis; VEGF, Vascular endothelial growth factor. 
  
Int. J. Mol. Sci. 2015, 16 11301 
 
 
6.1.1. Markers of Athero-Thrombosis and Inflammation 
It was previously reported that a combination of β-2-microglobulin (B2M), cystatin C, high-sensitivity 
C-reactive protein (hsCRP) and glucose was associated with PAD [65,66]. Plasma B2M levels and 
parameters of arterial stiffness such as aortic pulse wave velocity and augmentation index have been 
reported to be significantly increased in PAD patients [67]. Some studies have shown that combining 
these circulating markers of inflammation and atherosclerosis with clinical parameters may improve 
the identification of PAD patients [65,66,71]. A previous nested case-control study reported an increased 
relative risk of PAD (2.8, 95% CI: 1.3–5.9) for subjects in the highest hsCRP quartile compared with 
the lowest quartile [89]. 
The levels of a number of lipids and fat related markers have also been reported to be differentially 
regulated in PAD patients. A recent lipidomic analysis comparing serum lipid profiles in 168 patients 
with PAD and 161 abdominal aortic aneurysm patients showed that a group of linoleic acid-containing 
triacylglycerols and diacylglycerols were negatively associated with PAD presence [90]. Furthermore, 
combining lipidomic features with traditional risk factors significantly improved stratification of 
patients with PAD and abdominal aortic aneurysm. The levels of total and high molecular weight 
adiponectin were reported to be significantly lower in women developing PAD [72]. Oxidized 
phospholipids (OxPL) on Apo-B100-containing lipoproteins (OxPL/ApoB) and the major lipoprotein 
carrier of OxPL, named lipoprotein-a (Lp-a), have been reported to be positively associated with  
risk of PAD [73]. Additionally, apolipoprotein (Apo)-A1 and high-density lipoprotein (HDL) have 
previously been associated with PAD and Apo-AI and homocysteine (Hcy) were reported to be 
predictors of ABI [91]. It should also be noted that up to 30% of PAD patients have elevated serum 
levels of Hcy in comparison to 1% of the general population [17]. Previous randomised trials have 
failed to identify any clinical benefit of folic acid and cobalamin supplementation even though this 
intervention resulted in a reduction in serum Hcy concentration [92]. There are however a number of 
ongoing clinical trials examining the benefits of such supplementation in PAD patients [92–94]. 
Patients with asymptomatic PAD have been reported to have a defined profile of pro-inflammatory 
markers with significantly higher levels of interleukin (IL)-6, E-selectin and matrix metalloproteinase 
(MMP)-2, MMP-9 and significantly reduced levels of transforming growth factor (TGF)-β1 [82]. 
Recently, a number of novel markers, such as Rho-kinase activity [78] and human cartilage 
glycoprotein-39 (HCgp-39/YKL-40) [79], have been highlighted as markers of atherosclerosis. The 
ratio between plasma levels of macrophage scavenger receptor CD163 and tumor necrosis factor-like 
weak inducer of apoptosis (TWEAK) was also shown to be a potential biomarker of athero-thrombosis 
in asymptomatic PAD subjects [80]. Since atherosclerosis is a systemic disease, most of these circulating 
markers may not be specific to PAD but rather reflect the underlying atherosclerotic burden. The 
paraoxonases (PON) retard lipoprotein oxidation and have been suggested to have anti-atherogenic 
properties including reducing low density lipoprotein oxidation, reducing oxidative stress, promoting 
reverse cholesterol transport from macrophages and normalizing vascular endothelial function. PON-1 
activity has been suggested to modulate endothelial function in patients with PAD [95]. Circulating 
levels of PON-3 have been positively associated with B2M, chemokine ligand 2 (CCL2) and hsCRP in 
CAD, but not in PAD patients [81]. Since atherosclerosis is often widespread, it may be difficult to 
identify specific markers relating to PAD. Thus, markers that are altered in atherosclerosis in general 
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might be of limited clinical application in identifying PAD patients specifically since most of them do 
not show a unique association with PAD. 
6.1.2. Markers of Oxidative Stress 
An interesting observation was reported recently in relation to gender and racial differences in 
endothelial oxidative stress in patients with symptomatic PAD [96]. Female African American patients 
with symptomatic PAD were observed to have increased markers of oxidative stress and elevated 
levels of circulating pro-inflammatory biomarkers in comparison to males. The women also showed 
limited peripheral microcirculation, exercise performance, and ambulatory activity compared to male 
PAD patients. The findings were suggested to support the use of biomarkers related to oxidative stress 
in identifying symptomatic female PAD patients requiring interventions. 
A number of reports suggest that markers of oxidative stress [97–99], such as reactive oxygen 
species (ROS), are consistently increased in patients with PAD. The bioavailability of ROS within the 
circulation depends on their rate of formation, by mitochondrial enzymes such as NADPH oxidase 
(NOX) and xanthine oxidase (XO), and their rate of clearance, through the antioxidant defense  
system [100]. Furthermore, the bioavailability of NO depends on the balance maintained between the 
formation of NO and its removal, which is partly dependent on the reaction of NO with ROS. NO is  
an important component of the complex system that regulates vascular resistance and blood flow 
distribution [101]. PAD is associated with decreased production of NO [102,103]. 
Nicotinamide adenine dinucleotide phosphate oxidase (NOX)-2, is a multicomponent enzyme and 
the catalytic core of NADPH oxidase. NOX-2 mediates electron transfer from NADPH oxidase to 
molecular oxygen, and is the most important producer of ROS. Compared to controls, patients with 
PAD have been reported to have enhanced soluble NOX-2-derived peptides, isoprostanes and reduced 
serum levels of NO and flow mediated dilation [76]. CLI patients have also been reported to have 
reduced levels of nicotinamide adenine dinucleotide (NADH) and increased levels of NAD+ within 
their gastrocnemius muscles [104]. These findings suggest that an altered ratio of NAD and NADH within 
the circulation might reflect a compromised metabolic and redox state in PAD patients. Furthermore, 
plasma levels of ROS components have been reported to be increased in IC patients [52,77]. 
6.1.3. Markers of Vascular Remodeling 
Reduced circulating concentrations of a number of proteins involved in ECM remodeling, such as 
TGF-β1, have been reported in PAD patients [82]. Another protein proposed to be a valuable biomarker 
of vascular inflammation, as well as PAD presence, is the soluble receptor for advanced glycation end 
products (sRAGE). It was reported that circulating concentrations of sRAGE were reduced in PAD 
patients [83]. Serum VEGF has been reported to be positively associated with PAD in one small study, 
however a larger study assessing plasma VEGF reported no association [71]. Plasma thrombospondin 
(TSP)-1 has also been reported to be upregulated in PAD patients [86]. Furthermore, TSP-1 has been 
reported to be expressed in newly formed vessels in PAD patients receiving local injections of bone 
marrow mononuclear cells and therefore could be reflective of therapeutic angiogenesis. In vitro and  
in vivo studies have suggested that recombinant human TSP-1 had a negative effect on angiogenesis. 
siRNA mediated TSP-1 inhibition has been reported to promote endothelial colony forming cells (ECFC) 
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proliferation and recombinant human TSP-1 significantly enhanced ECFC adhesion [86]. Furthermore, 
a short peptide derived from the N-terminal part of TSP-1 named TSP-Hep-I also significantly 
enhanced the adhesion potential of ECFCs. Further work is needed to assess the value of circulating 
TSP-1 concentrations in identifying and providing prognostic information for PAD patients. 
6.1.4. Circulating Progenitor Cells 
The number of circulating endothelial progenitor cells (EPC) has been reported to be associated 
with atherosclerosis and CVD however further work is needed to assess its value as a reliable 
biomarker for PAD [105]. It has, for example, been reported that compared to controls, the number of 
EPCs and the plasma pentraxin-3 concentration were increased in IC patients, but not in those with 
CLI [87]. In another study it was reported that cells expressing markers such as CD34(+) or CD133(+) 
circulated in lower numbers in PAD patients compared to healthy controls [88]. The cells expressing 
CD34(+) or CD133(+) are believed to represent bone marrow progenitors and studies in mice models 
have suggested they are involved in angiogenesis [80]. A thermal therapy using far infrared rays within 
a sauna (Waon therapy) has been reported to promote mobilization of CD34(+) cells and augment 
ischemia induced angiogenesis in mice with hind limb ischemia [106]. 
Overall, while several biomarkers have been associated with PAD presence currently none of  
these markers have been consistently demonstrated to improve detection of PAD. In this context, 
markers of oxidative stress and circulating progenitor cell populations warrant further attention. 
Further investigations in which markers are examined in large and repeated groups of patients are 
needed to better examine the potential of using these circulating markers in clinical practice. 
6.2. Markers Associated with the Severity and Outcome of PAD 
Biomarkers may not only be useful in determining the presence or absence of a disease, but could 
also be useful in predicting patient outcomes. A detailed analysis of a reliable biomarker when 
combined with established risk factors could assist in stratifying patients at high risk and for selecting 
optimal treatment. Many published studies have assessed the value of prognostic biomarkers in small 
groups of patients. However, data that available markers can lead to consistent improvements in 
clinical management is currently not convincing. It is important that the associations between markers 
and prognosis observed in smaller isolated studies are followed up by validation in larger cohort 
studies in independent populations. This section of the review focuses on the most commonly reported 
circulating biomarkers linked to inflammation, endothelial dysfunction, angiogenesis and vascular 
remodeling and their relationship with PAD severity and outcomes such as reduced ABI, amputation 
and mortality (Table 2). 
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Table 2. Examples of circulating biomarkers reported to be associated with the severity 
and outcome of peripheral artery disease. 
Circulating Biomarkers Assessed Sample Size (N) 
Sample 
Studied 
Association with PAD Severity Refs. 
hsCRP, albumin, α-2 macroglobulin, 
fibrinogen, IL-1β, IL-1 receptor 
antagonist, IL-6, IL-6 receptor, IL-10, 
IL-18, TNF-α, & TGF-β 
InCHIANTI study; PAD (955) Serum 
Higher levels of IL-1 receptor 
antagonist, IL-6, fibrinogen and 
hsCRP in PAD patients. 
[107] 
hsCRP, DD, TAT III & vWF  IC (132) & CLI (30) Plasma 
Higher levels of hsCRP, vWF, and TAT 
III in CLI compared to patients with IC. 
[108] 
hsCRP, fibrinogen & SAA PAD (91) Plasma 
hsCRP, fibrinogen, and SAA levels 
were significantly associated with CLI; 
elevated hsCRP correlated with adverse 
graft-related or cardiovascular events. 
[109] 
hsCRP, DD, IL-6,  
VCAM-1, ICAM-1 & Hcy 
Walking and Leg Circulation 
Study (WALCS); PAD (423) 
Serum 
Higher levels of inflammation markers 
and DD were associated with poorer 
lower extremity performance. 
[110] 
hsCRP, DD, SAA & fibrinogen  PAD (337) Serum 
Elevated baseline levels of 
inflammatory markers and DD were 
associated with greater decline in the 
physical performance. 
[111] 
hsCRP PAD (225) Plasma 
A risk prediction model including 
hsCRP combined with traditional risk 
factors, renal function, and nutrition 
had excellent discriminatory ability 
in predicting all-cause mortality in 
patients with clinically advanced 
PAD undergoing bypass surgery. 
[112] 
hsCRP PAD (118) Plasma 
Increased pre-procedural hsCRP 
levels were associated with major 
adverse limb events and late 
cardiovascular events. 
[113] 
hsCRP 
Hemodialysis patients 
undergoing endovascular 
therapy for PAD (234)  
Serum 
Elevated pre-procedural hsCRP 
levels were associated with  
re-intervention or above ankle 
amputation and any-cause death after 
endovascular therapy.  
[114] 
hsCRP 
European Prospective 
Investigation into Cancer and 
Nutrition (EPIC)-Norfolk cohort; 
Healthy participants (18,450) 
Serum 
In the EPIC-Norfolk cohort, hsCRP was 
associated with nonfatal PAD events.  
[115] 
hsCRP, LDL & HDL Total PAD (100); IC (73) Blood 
Walking disability in PAD was 
associated with arterial endothelial 
dysfunction; Endothelial dysfunction 
was more significantly associated 
with walking disability in IC. 
[116] 
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Table 2. Cont. 
Circulating Biomarkers Assessed Sample Size (N) 
Sample 
Studied 
Association with PAD Severity Refs. 
ApoA-I, HDL, Hcy,  
folate & vitamin B12 
Elderly volunteers from  
rural Sicily (667) 
Serum 
Decreased ApoA-I and increased 
Hcy were predictors of ABI. 
[91] 
VCAM-1, ICAM-1 & MCP-1 PAD (112) Serum 
Increased sVCAM-1 and sICAM-1 
were associated with PAD.  
[117] 
ICAM-1, leptin, Apolipoprotein-CIII PAD (148) Serum 
African American women with 
symptomatic PAD had an increased 
oxidative stress related markers 
compared with men. 
[96] 
MPO PAD (406) Plasma 
Plasma level was useful for risk 
stratification of PAD. 
[118] 
TRAP-6-inducible  
P-selectin expression 
PAD (108) Blood 
Low thrombin generation potential 
was associated with an 11.7-fold 
increased risk of future 
atherothrombotic events. 
[119] 
Galectin-3 CLI (55) Serum Increased levels of Galectin-3 in CLI. [120] 
NT-pro-BNP 
PCA (100), PAD (300) & 
healthy controls (300) 
Serum 
Patients with PCA had higher levels 
of NT pro-BNP than PAD and 
controls suggestive of an adverse 
hemodynamic milieu and  
increased risk for adverse 
cardiovascular outcomes. 
[121] 
NT-pro-BNP PAD (481) Serum 
Higher levels of NT-pro-BNP were 
independently associated with a 
lower ordinal walking category or 
functional capacity. 
[122] 
Ang2, Tie2, VEGF,  
VEGFR-1 & PlGF  
PAD (46) & healthy controls (23) Plasma 
Levels of VEGF and sTie2 were 
significantly increased in CLI. 
[85] 
VEGF-A 165b PAD (18) Serum 
Increased anti-angiogenic  
VEGF-165b and a corresponding 
reduction in levels of the  
pro-angiogenic VEGF-A165a. 
[123] 
Abbreviations: ALI, Acute limb ischemia; Ang2, Angiopoietin-2; CLI, Critical limb ischemia; DD, D-Dimer; 
Hcy, Homocysteine; HDL, High-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; IC, 
Intermittent claudication; ICAM, Intercellular adhesion molecule; IL, Interleukin; LDL, Low-density 
lipoprotein; MCP-1, Monocyte chemotactic protein 1; MPO, Myeloperoxidase; MMP, Matrix 
metalloproteinase; NO, Nitric oxide; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; PAD, 
Peripheral artery disease; PCA, Poorly compressible arteries; PlGF, Placenta growth factor; SAA, serum 
amyloid A; TAT III, Thrombin-antithrombin III; TGF-β, Transforming growth factor-β; TIMP, Tissue 
inhibitor of matrix metalloprotenase; TNF, Tumour necrosis factor; VCAM, Vascular adhesion molecule; 
VEGF, Vascular endothelial growth factor; vWF, von Willebrand factor. 
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6.2.1. Markers of Inflammation 
Multiple studies have reported that inflammation associated biomarkers circulate at higher levels in 
PAD patients with more severe disease [68,70,107–109,124] (Table 2). Cholesterol undergoes oxidation 
via both enzymatic stress-driven and free radical-mediated mechanisms and generates a range of 
oxysterols. Accumulation of hydroxycholesterols (HC) such as 25-HC, 27-HC and 24S-HC in the 
aortic intima was associated with systemic inflammatory activity and advanced atherosclerotic disease 
in individuals with severe PAD [125]. In the National Health and Nutrition Examination Survey of 
American men and women aged ≥40 years (n = 4787), elevated levels of hsCRP, fibrinogen, and 
leukocyte counts were associated with lower ABI values [68]. High levels of the inflammatory markers 
IL-6, hsCRP, soluble vascular adhesion molecule-1 (sVCAM-1) and soluble intercellular adhesion 
molecule-1 (sICAM-1) have been reported to be associated with accelerated functional decline in PAD 
patients [69,82,110,111,117] and with PAD complications such as amputation or general complications 
such as MI, stroke and death (Table 2). A risk prediction model was developed in a prospective cohort 
study of patients with clinically advanced PAD undergoing lower extremity bypass surgery (n = 225, 
followed up for a median of 893 days). The study showed that the traditional risk factors and 
circulating markers of inflammation such as hsCRP, sVCAM-1, renal function, and nutrition had 
excellent discriminatory ability in predicting all-cause mortality in PAD patients [112]. hsCRP has 
been shown to be an independent predictor of adverse cardiovascular outcomes and increased risk of 
secondary interventions or limb loss in PAD patients [126]. Elevated pre-procedural serum levels of 
hsCRP have been associated with requirement for re-intervention or above ankle amputation and 
mortality after endovascular therapy in haemodialysis patients with PAD [114]. Similar findings have 
been reported in other PAD patient groups [113]. A recent large prospective cohort study involving 
18,450 participants (European Prospective Investigation into Cancer and Nutrition (EPIC)—Norfolk 
cohort) reported a strong and independent association between elevated hsCRP levels and an increased 
risk of PAD complications [115]. 
6.2.2. Markers of Oxidative Stress and Endothelial Damage 
Myeloperoxidase (MPO) is a peroxidase enzyme stored in neutrophils and a key mediator of 
inflammatory and redox-dependent processes in atherosclerosis. MPO has been reported to promote 
atherosclerosis via inducing oxidative stress in animal models [127,128]. A previous study suggested 
the potential value of using plasma MPO for risk stratification of major adverse events in PAD  
patients [118]. Similarly, in vitro thrombin generation potential was reported to correlate inversely 
with protease-activated receptors (PAR)-1-mediated platelet activation and was linked to the 
occurrence of athero-thrombotic events in patients with PAD [119]. The protein Galectin-3 is a soluble 
β-galactoside-binding lectin protein that has been implicated in athero-thrombosis and suggested as  
a biomarker for heart failure [129]. A five-year follow-up study of 309 PAD patients reported that 
circulating Galectin-3 concentrations were significantly and independently associated with an increased 
risk for CVD mortality (OR = 2.24, 95% CI: 1.06–4.73; p < 0.05) suggesting its potential use as  
a prognostic marker [130]. 
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Arterial occlusion results in inadequate oxygen supply to the lower extremities and concurrent 
defective clearance of toxic metabolites. The net result is the accumulation of ROS, leading to tissue 
necrosis and microcirculatory damage that eventually result in irreversible deterioration and injury to 
the endothelial lining [131,132]. A previous study reported that reduced walking ability in PAD 
patients was associated with arterial endothelial dysfunction [116]. In another study however circulating 
concentrations of the endothelial marker NO were not associated with the severity of PAD [69]. 
Plasma levels of ROS markers, such as thiobarbituric acid-reactive substances (TBARS), sICAM-1 
and antioxidants were increased in IC patients indicating that increased ROS production and damaged 
electron transport chain complexes may contribute to PAD and may serve as potential markers for its 
severity [52,77,133]. 
A recent report suggests that serum N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) levels 
are associated with functional capacity in patients with PAD and may be a marker of hemodynamic 
stress in these patients [122]. Natriuretic peptides are mainly secreted from the heart in response to 
increased wall stress and NT-pro-BNP is elevated in patients with increased left ventricular mass and 
coronary heart disease, in addition to PAD [134]. Higher levels of circulating NT-pro-BNP have been 
associated with increased CVD mortality in PAD patients [113], and also patients with CHD [135,136]. 
Serum NT-pro-BNP levels were reported to be significantly higher in patients with poorly compressible 
arteries (PCA) than in those with PAD [121]. PCA occur due to medial arterial calcification and 
patients with PCA have an elevated ABI. Medial arterial calcification is associated with a number of 
chronic disease conditions and an increased risk predictor for CVD events and lower extremity 
amputation [137]. Even though medial arterial calcification and intimal calcification (which is a hallmark 
of atherosclerosis) may coexist, these two conditions are suggested to be distinct [138]. A recent report 
on the histopathological assessment of PAD (176 upper and lower leg artery specimens) patients 
highlights that the most common observations were medial calcification (present in 72% of arteries 
examined) and intimal thickening without lipid (present in 68% of arteries examined). Classical 
atherosclerosis was only identified in 23% of arteries [139]. Non-atheromatous intimal thickening  
was frequently observed, resulting in complete occlusion in some vessels. This suggests that vascular 
lesions in PAD patients may have additional pathological mechanisms other than atherosclerosis alone. 
6.2.3. Markers of Vascular Remodeling 
One of the most studied markers of angiogenesis in PAD is VEGF and its receptors R1 and R2. 
VEGF-R1 is characteristically up-regulated by hypoxia and its soluble form has been proposed as  
a marker for CLI. Patients with advanced PAD have been reported to have elevated serum and tissue 
levels of VEGF compared to age matched healthy volunteers [84,85]. Furthermore, VEGF values in 
Fontaine class IV patients have been reported to be almost double that in healthy controls. High 
circulating VEGF levels have been associated with poor outcomes, such as major amputation, 
suggesting serum VEGF to be a potential marker for PAD severity. These findings could be interpreted 
as suggesting that administration of VEGF in an attempt to achieve therapeutic angiogenesis for CLI 
may not be safe [140]. It is however likely that the association of high VEGF concentrations with poor 
outcome reflects reverse causality as a response to the severity of ischemia rather than a cause. 
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Another, member of the VEGF family is VEGF-A, which exists as several isoforms produced as  
a result of alternative splicing. Reduced levels of circulating levels of total VEGF-A have been observed 
in IC patients compared to healthy controls [71]. Lower levels of total VEGF-A have also been associated 
with a reduction in capillary to muscle fibre ratio in PAD subjects [141]. A recent report suggested that 
in PAD, vascular insufficiency occurs in spite of elevated levels of total VEGF-A [123]. However, 
further analysis showed that PAD was associated with elevated levels of a VEGF-A splice isoform, 
VEGF-A165b and a corresponding reduction in levels of the VEGF-A165a splice isoform. Further 
studies in a rodent model suggested that VEGFA-165b had anti-angiogenic properties and the  
VEGF-A165a isoform was pro-angiogenic. Studies in a mouse model of PAD suggested that 
administration of VEGF-A165b inhibited revascularization [123]. Additional studies are warranted in 
patients in different PAD stages to understand the use of various VEGF-A isoforms as markers of 
angiogenesis status. Higher levels of plasma angiopoietin-2 (Ang2), and soluble Tie2 (sTie2) have 
been reported in patients with CLI compared to those with IC [85], indicating that there are other 
potential circulating biomarkers of disease severity that warrant attention. 
The ECM plays a major role in regulating angiogenesis and in vitro and in vivo studies suggest  
a crucial role of proteolytic enzymes and matrix proteins in creating a permissive microenvironment to 
promote blood vessel sprouting [142–144]. Reorganization of the ECM, promoted by MMPs, creates 
space required for expansive remodeling of the pre-existing collaterals. Circulating levels of MMP-2, 
MMP-9, MMP-19 and Tissue inhibitor of metalloproteinase (TIMP)-1 have been reported to be 
elevated in CLI patients [74,82,145]. Furthermore, elevated plasma levels of MMP-2 and MMP-9 have 
been associated with PAD severity [146]. A previous study reported that the levels of both MMP-2 and 
MMP-9 (both the latent and the active forms) significantly increased during the active phase of limb 
reperfusion [147]. This temporal increase in MMP activity coincided with enhanced exposure of the 
unique cryptic collagen epitope (HU177) which has been previously implicated in angiogenesis in 
ischemic muscle. These findings suggest an important role for collagen remodeling during the active 
phase of ischemic limb reperfusion. Furthermore, studies in an animal model suggest that MMP-9 is 
essential for ischemia induced neovascularization by modulating bone marrow derived EPCs. MMP-9 
deficiency impairs ischemia-induced neovascularization, through a reduction in EPC mobilization, 
migration, and vasculogenesis functions [148]. Additionally, use of ischemic muscle markers is only 
likely to be practical clinically if circulating forms of these markers are reflective of those in the 
muscle. It is not currently clear whether any reliable relationship exists between blood and muscle 
marker levels. 
7. Conclusions 
In this review, we have presented an overview of markers associated with PAD presence and 
outcome. A number of limitations exist for circulating markers currently identified. There is little 
consensus on which markers are consistently associated with PAD and there are definite challenges  
in identifying markers that are PAD-specific. The circulating markers should ideally reflect the 
changes occurring in the ischemic lower-limb muscles. In order to have clinical utility, the circulating 
biomarkers should predict risk independently of other established PAD risk factors. Furthermore,  
the circulating marker should be specific and sensitive and easily assayed. 
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Biomarkers that could effectively predict PAD development, progression and outcome could be 
extremely useful in the clinical setting [149–151]. Ideally such markers would also identify patients 
best suited to different types of treatment. Currently, however, there is no convincing evidence that the 
markers investigated are reliable and specific. Even though novel markers such as Rho-kinase activity, 
human cartilage glycoprotein-39, TWEAK and PON-3, have been associated with PAD presence, their 
validity as reliable marker is unclear as these individual reports are frequently not followed by other 
replication studies. Some markers of inflammation, such as B2M, hsCRP and interleukins, oxidative 
stress, such as NO and NOX-2, ECM remodeling, such as TGF-β1, TSP-1 and VEGF, and circulating 
progenitor cell populations have been consistently associated with PAD presence (Figure 2).  
Similarly, markers of inflammation, such as hsCRP and sVCAM-1, oxidative stress, such as MPO and  
NT-pro-BNP, ECM remodeling, such as VEGF, VEGF-A isoforms and MMPs, have been consistently 
associated with PAD severity. Since cell therapy is a promising approach in PAD management, 
assessment of circulating stem cell populations may be of potential value. A comprehensive 
characterization of the circulating progenitor cell markers may be useful in identifying patients  
suitable for cell therapies. It should also be noted that initial investigations often over-estimates the 
effect size of a discovered association and thus it is important to re-assess findings in different 
populations. Thus it is important that prospective studies using large patient populations are conducted 
to validate biomarkers of interest to gain insight into their “real-world” benefit as diagnostic or 
prognostic aids. 
In summary: (1) PAD is multifactorial; therefore single biomarker may not be powerful enough for 
reliable diagnosis and/or prognosis. Rather a combination of risk factor and circulating marker data 
may be needed; (2) Identifying a marker specific to PAD rather than general athero-thrombosis may be 
technically challenging; (3) Despite considerable effort, no biomarkers have been currently shown  
as sufficiently robust to be incorporated into clinical practice. Even though a number of currently 
identified circulating markers show promise, further larger studies focused on the clinical value of  
such markers over existing risk predictors are needed. 
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Figure 2. Circulating biomarkers in peripheral artery disease. A schematic depiction of the 
stages at which circulating biomarkers could be informative in the peripheral artery disease 
(PAD) course. Since PAD is multifactorial it is likely that a single biomarker may not be 
sufficient to predict diagnosis or prognosis. Since PAD development and progression is 
due to the interaction of multiple factors, it is possible that the combination of a number of 
biomarkers may be preferable to a single maker. Abbreviations: ABI, Ankle brachial 
index; Ang-2, Angiopoetin-2; ApoA1, Apolipoprotein A1; B2M, β-2-microglobulin; EPC, 
Endothelial progenitor cell; HCgp, Human cartilage glycoprotein; Hcy, Homocysteine; 
hsCRP, high sensitivity C-reactive protein; IL, Interleukin; Lp-a, Lipoprotein-1; MMP, 
Matrix mettalloprotenase; MPO, Myeloperoxidase; NO, Nitric oxide; NOX, NADPH 
Oxidase; NT-pro-BNP, N-terminal pro-B-type natriuretic peptide; OxPL/ApoB, Oxidised 
phospholipids on ApoB100 containing lipoproteins; PAD, Peripheral artery disease; PAR, 
Protease activated receptor; PON, Paraoxonase; sICAM-1, soluble Intercellular adhesion 
molecule-1; sRAGE, soluble receptor for advanced glycation end product; sTie-2, soluble 
Tyrosine kinase with immunoglobulin-like and EGF-like domains 2; sVCAM-1, soluble 
Vascular cell adhesion molecule-1; TBARS, Thiobarbituric acid-reactive substrates; TGF, 
Transforming growth factor; TWEAK, Tumour necrosis factor like weak inducer of 
apoptosis; TSP, Thrombospondin; TIMP, Tissue inhibitor of matrix metalloproteinase; 
VEGF, Vascular endothelial growth factor. 
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